We use cookies on this site in order to make it works, and for the traffic analysis.
You can refuse or configure cookies by purposes.
Another message from the Google Adsense consent management platform will ask you for your choices relating to the use of your personal data via cookies for advertising.
We thank you to accept cookies which makes this site work.

Teduglutide 1

Phase III clinical studies have shown that treatment with teduglutide (TED) was associated with at least 20% reduction in PS at 6 months in SBS adult patients. Due to the heterogeneity of patients in randomized studies and the cost of the drug, the ESPEN guidelines focused on the need to identify SBS patients who are candidates for growth factor treatment. Currently, the number of patients treated with these agents is still low. It is advised that these treatments should only be used under the guidance of a physician experienced in the management of SBS with an expectation that these patients need to be monitored closely during and potentially after their use. Since potential longterm complications are unknown, careful long-term monitoring is required. In addition, careful ongoing evaluation of the clinical benefits has to be prudent.
To improve the quality of care, it seems urgent to propose clinical practice consensus related to indication of Teduglutide, assessment before drug initiation, and modalities of follow up.
First step :
- Propose a survey to centres with expertise on chronic intestinal failure who prescribe Teduglutide ( or not ?) to evaluate the different practices

Second step :

- Based on the results of the above survey, to elaborate a specific questionnaire to develop consensus clinical practice guidelines for Teduglutide use

For each question, several answers are possible. In some cases, some specification can be needed, please be as succinct as possible.

For each question, even you can’t prescribe teduglutide, please response if you could prescribe teduglutide in your country

If no, please clarify : no indication or no reimbursement in the country

mandatory answer

Question 1

Hospital

Question 2

You believe that the drug can be used in SBS patients requiring PS:

Comments

Question 3

At which frequency do you perform the clinical follow up and what do you monitor?
If you consider a different follow up related to intestinal anatomy, please fill in a table for each condition.

For each month please specify how many time (for example : diuresis month 1 every weeks correspond to 4 per month, diuresis month 6 2 per month)

month 1month 2month 3month 4
diuresis
stoma output/stool quantity
entry / exit check
edema signs
cardiac auscultation
weight
oral intake
beverage
other

Comments




You too, create your online questionnaire!
It's free and easy.
Let's go!
▲